The DEA has proposed placing tianeptine into Schedule I, opening a public comment period that runs through August 7. The move targets a compound that occupies an unusual position in American drug policy: approved and prescribed as a conventional antidepressant in dozens of other countries, but never approved by the FDA, and for years sold in the United States through the dietary-supplement retail channel, openly marketed under names like Tianaa and ZaZa in gas stations, convenience stores, and smoke shops, despite never meeting the FDA’s legal definition of a dietary ingredient.

What tianeptine actually is

Tianeptine is an atypical tricyclic antidepressant, structurally related to the tricyclic class but with a distinct mechanism, used clinically abroad at low, prescribed doses. In the US retail products that built its notoriety, the doses are a different story entirely. At the elevated doses found in supplement products, tianeptine acts as a mu-opioid receptor agonist, the same receptor family targeted by heroin and prescription opioids, and users have described its retail products’ effects and withdrawal syndrome as functionally opioid-like. That is the origin of its “gas station heroin” nickname, a label the FDA itself has used in a consumer product-trend alert.

The regulatory gap it exploited

Tianeptine has never met the FDA’s legal definition of a dietary ingredient, and the agency has published multiple consumer alerts warning against tianeptine products since 2018. But a federal alert is not a federal scheduling action, and until this proposal, tianeptine was not controlled under the Controlled Substances Act at all. That left enforcement to a patchwork of state law: a growing list of states have banned or restricted it individually, but in any state that had not acted, tianeptine remained legally purchasable over the counter. Poison-center data shows tianeptine exposure calls climbing as that gap persisted, from 11 across the entire 2000-to-2013 period to 207 in 2014 through 2017 alone, with a later analysis putting reported exposures up roughly 1,400 percent from 2015 to 2023; kratom co-ingestion accounted for more than a fifth of reported exposures. Separately, DEA forensic laboratories recorded 268 tianeptine encounters between March 2017 and February 2026. Alongside documented dependence and withdrawal cases, the DEA’s own scheduling filing documents fatal cases directly, including two overdose deaths in Texas and a Pennsylvania death a coroner attributed to tianeptine toxicity.

What the proposal would do

If finalized, Schedule I placement would apply the full regulatory and criminal framework governing manufacture, distribution, import, export, research, and possession, the same legal category as heroin and LSD, superseding the state-by-state patchwork entirely. This is a standard notice-and-comment rulemaking under the Controlled Substances Act’s normal scheduling authority, not an emergency or temporary order, which means it follows the slower, more procedurally complete path: a public comment period through August 7, the possibility of a formal hearing if requested, and a final rule sometime after that record closes.

The pattern this fits

Tianeptine is not chemically related to kratom, but its regulatory story runs on the same rails, unapproved compound, retail-supplement framing, opioid-adjacent pharmacology at the doses actually sold, and a state-level response that federal action is now moving to standardize. It is also the third distinct DEA scheduling action against this general retail category inside two weeks: a notice of intent to temporarily schedule concentrated 7-hydroxymitragynine above a set potency threshold, a separate temporary scheduling notice for a cluster of mitragynine-derived analogs found in overdose and toxicology data, and now a full, permanent Schedule I proposal for tianeptine. Three different legal mechanisms, a concentration threshold, emergency temporary scheduling, and standard permanent rulemaking, applied within the same short window to substances sharing the same retail channel is a reasonable signal that the unregulated botanical-and-novel-compound supplement shelf is where DEA’s enforcement attention currently sits.

The caveats

This is a proposal, not a final rule, and the comment period exists precisely because scheduling decisions can and do change in response to the record built during it. Nothing about tianeptine’s international use as a legitimately prescribed antidepressant is altered by this action; the proposal targets the unapproved, high-dose retail products specific to the US market, not the compound’s therapeutic profile at clinically appropriate doses elsewhere. And, as with the kratom threshold action, a federal scheduling decision does not retroactively resolve years of accumulated harm from a product that spent most of its US retail life sold through a regulatory gap rather than genuine legal sanction.

The frame

The regulatory story here is less about tianeptine specifically than about a category: compounds that reach consumers through supplement and retail law rather than pharmaceutical law, accumulate a real harm record while regulators work state by state, and eventually draw a federal scheduling response once that record is hard to ignore. Kratom’s concentrated derivatives and tianeptine are both moving through that same arc within weeks of each other. Whether that reflects a genuinely coordinated enforcement push or simply several long-building dockets landing in the same news cycle is not yet clear from the public record, but the pattern itself, three scheduling mechanisms, one retail channel, two weeks, is worth tracking as its own regulatory story independent of any single compound.